Key clinical point: Addition of enzalutamide to ADT improves outcomes of metastatic hormone-sensitive prostate cancer.
Major finding: Compared with placebo plus ADT, enzalutamide plus ADT prolonged radiographic progression-free survival (median not reached with enzalutamide vs. 19.45 months with placebo; hazard ratio, 0.39; P less than .0001).
Study details: A phase, 3 randomized, controlled trial among 1,150 men with metastatic hormone-sensitive prostate cancer (ARCHES trial).
Disclosures: Dr. Armstrong disclosed that he has a consulting or advisory role with, receives research funding (institutional) from, and receives travel, accommodations, and/or expenses from Astellas – among other disclosures. The trial was sponsored by Astellas.
Armstrong AJ et al. GUCS 2019, Abstract 687.